Cart
sales@molnova.com
NAMI-A
CAS No. 201653-76-1
NAMI-A( —— )
Catalog No. M33439 CAS No. 201653-76-1
NAMI-A, a ruthenium-based compound, selectively targets tumor metastasis by inhibiting cancer cell adhesion and migration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 71 | Get Quote |
|
| 5MG | 116 | Get Quote |
|
| 10MG | 163 | Get Quote |
|
| 25MG | 343 | Get Quote |
|
| 50MG | 631 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNAMI-A
-
NoteResearch use only, not for human use.
-
Brief DescriptionNAMI-A, a ruthenium-based compound, selectively targets tumor metastasis by inhibiting cancer cell adhesion and migration.
-
DescriptionNAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases,inhibits the adhesion and migration.In vitro:NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. In vivo: The reference for NAMI-A is 35 mg/kg/day.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFAK
-
RecptorFAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number201653-76-1
-
Formula Weight458.18
-
Molecular FormulaC8H15Cl4N4ORuS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 8.28 mg/mL (18.07 mM)
-
SMILES[H+].O=[S](C)(C)[Ru+3]([Cl-])([Cl-])([Cl-])([Cl-])[N]=1C=CNC1.N=1C=CNC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sava G et al. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res. 2003 May;9(5):1898-905.?
molnova catalog
related products
-
Tasimelteon
Tasimelteon is a melatonin receptor agonist that is used for the treatment of non-24 hour sleep-wake disorder in blind individuals.
-
Ifebemtinib
Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas.
-
GSK215
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader (pDC50= 8.4), designed using the FAK inhibitor VS-4718 and a binder for the VHL E3 ligase, capable of inducing rapid and prolonged FAK degradation.
